CTX 114
Alternative Names: CTX-114Latest Information Update: 27 Mar 2025
At a glance
- Originator Character Biosciences
- Class Eye disorder therapies
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 27 Mar 2025 Pharmacodynamics data from preclinical trials in Wet age-related macular degeneration and Dry macular degeneration released by Character Biosciences
- 07 Feb 2025 Character Biosciences plans clinical trial in Dry macular degeneration in 2025 (Character Biosciences pipeline, February 2025)
- 04 May 2024 Preclinical trials in Dry macular degeneration in USA (unspecified route), before May 2024 (Character Biosciences pipeline, February 2025)